about
Enhancing cytotoxic and apoptotic effect in OVCAR-3 and MDAH-2774 cells with all-trans retinoic acid and zoledronic acid: a paradigm of synergistic molecular targeting treatment for ovarian cancer.Greater patient access to immuno-oncology therapies-what can policymakers do?Capecitabine maintenance therapy following docetaxel/capecitabine combination treatment in patients with metastatic breast cancer.Efficacy and safety of bevacizumab plus capecitabine and irinotecan regimen for metastatic colorectal cancer.Tumor characteristics and metastatic sites may predict bevacizumab efficacy in the first-line treatment of metastatic colorectal cancer.Sexual dysfunction in cancer patients: a review.Octreotide in combination with AT-101 induces cytotoxicity and apoptosis through up-regulation of somatostatin receptors 2 and 5 in DU-145 prostate cancer cells.Combination of zoledronic acid and serine/threonine phosphatase inhibitors induces synergistic cytotoxicity and apoptosis in human breast cancer cells via inhibition of PI3K/Akt pathway.Docetaxel in combination with octreotide shows synergistic apoptotic effect by increasing SSTR2 and SSTR5 expression levels in prostate and breast cancer cell lines.Enhanced cytotoxicity and apoptosis by thymoquinone in combination with zoledronic acid in hormone- and drug-resistant prostate cancer cell lines.Zoledronic acid increases cytotoxicity by inducing apoptosis in hormone and docetaxel-resistant prostate cancer cell lines.A diverse induction of apoptosis by trabectedin in MCF-7 (HER2-/ER+) and MDA-MB-453 (HER2+/ER-) breast cancer cells.Combination of AT-101/cisplatin overcomes chemoresistance by inducing apoptosis and modulating epigenetics in human ovarian cancer cells.Pretreatment with AT-101 enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis of breast cancer cells by inducing death receptors 4 and 5 protein levels.Comparison of XTT and Alamar blue assays in the assessment of the viability of various human cancer cell lines by AT-101 (-/- gossypol).Alveolar rhabdomyosarcoma originating from the uterine cervix.Targeting apoptosis in the hormone- and drug-resistant prostate cancer cell line, DU-145, by gossypol/zoledronic acid combination.Overcoming drug resistance in hormone- and drug-refractory prostate cancer cell line, PC-3 by docetaxel and gossypol combination.The Role of Body Mass Index in Triple Negative Breast Cancer.Cutaneous melanoma in Turkey: analysis of 1157 patients in the Melanoma Turkish Study.Pazopanib: a novel treatment option for aggressive fibromatosisIs it the time for metformin to take place in adjuvant treatment of Her-2 positive breast cancer? Teaching new tricks to old dogs.Survival analysis of metastatic colorectal cancer patients who were treated with the five major therapeutic agents over the course of disease.Common etiology of capecitabine and fluorouracil-induced coronary vasospasm in a colon cancer patient.Comparing time to disease progression of irinotecan and oxaliplatin-based chemotherapies in colorectal cancer patients with liver only metastasis.Pegylated liposomal doxorubicin in heavily pretreated epithelial ovarian cancer patients.Docetaxel and platinum combination chemotherapy in locally advanced or metastatic head and neck cancer.Effects of exercise on angiogenesis and apoptosis-related molecules, quality of life, fatigue and depression in breast cancer patients.AT-101 acts as anti-proliferative and hormone suppressive agent in mouse pituitary corticotroph tumor cells.Cancer patients' satisfaction with doctors and preferences about death in a university hospital in Turkey.Novel combination of docetaxel and thymoquinone induces synergistic cytotoxicity and apoptosis in DU-145 human prostate cancer cells by modulating PI3K-AKT pathway.Undifferentiated embryonal sarcoma of the liver in an adult patient: case report.Leptomeningeal carcinomatosis of gastric adenocarcinoma.The frequency and significance of radiologically detected indeterminate pulmonary nodules in patients with colorectal cancer.A novel angiogenesis inhibitor, sunitinib malate, in encapsulating peritoneal sclerosis.Fanconi's anemia and squamous cell carcinoma of the larynxInfluence of medical education on students' attitudes towards the elderlyRadiosensitization of hormone-refractory prostate cancer cells by gossypol treatmentDoes the tumor localization in advanced pancreatic cancer have an influence on the management of symptoms and pain?Screening for metastasis in primary breast cancer patients having four or more axillary lymph node involvement: is it really necessary?
P50
Q34075052-E2E1E29E-0F5C-4FF7-9195-85C370FA72C8Q35125347-634D3087-675E-41BC-A595-628AA9F52B80Q36085860-4E0A27BA-96D0-495C-9AA9-FC90259E4018Q37519352-AE130862-47F5-4BDC-AA83-A79AE86F35C0Q37561000-60CBCFFD-951A-49DD-8C25-4996F39CF256Q38171780-9BEF2937-CC5E-489E-8818-5C2C40B76025Q38822225-4C2F87FD-641A-459F-A73C-339A1D29C9C8Q38828243-44A0AF9C-6C3D-43EA-B5C6-FDAF8F824E53Q38880901-6280493D-2E26-4812-AD17-564EA8690CA9Q38925786-3E987861-17F4-400D-AD22-572AF4B69A07Q38949883-ECB680B7-7079-49C4-830D-9369881E0AC4Q39136446-7B210DBA-A441-430F-8F10-47B91416953AQ39220493-D7AD8DCD-A8E8-47D5-B302-54EE3F51BDB5Q39381054-C0B65C2E-AD82-474A-99E7-0FDF0473C548Q39655726-C74300B0-C97A-4CE8-AA1B-DD50CF6E5F79Q39746262-FF763DC1-F5BB-4BED-AF5C-B08BBD94D8B0Q39806434-F925F01A-3D18-4305-8DF9-B22037F78A43Q39872458-6F0A5520-85F8-4509-BF0F-DB8347801EAAQ40448226-AF80F60A-1131-4105-BC4A-0FF78A300178Q40489844-CDBF8912-6113-4396-AEEA-1EC91D68BD18Q42360701-593E7D8E-38DF-4253-B073-CEFCC62F03B5Q42456137-4F1DB71D-0AF3-4D7F-ADCA-2EE06DD2E541Q44624924-1029586A-5EB7-4AF1-B918-B43BBD723E02Q45258221-B2159D05-3313-4266-B9D6-550681C7DA47Q45694936-E65C22E8-88C7-4A3D-88A5-5D7BB25FE4F7Q46268146-9E273E0E-906E-42A9-98E9-64279BE5C1EAQ46538989-FBAAE82C-AA09-40FC-97C8-BB3CA03B253AQ48232163-F1AD8D1A-9218-4ABB-8625-35041CD9D385Q50524034-2BC25754-FC35-4073-823C-F81CE5CEAC4FQ51039404-683249B7-7E0C-455C-B5F8-EF4C5471B058Q51066360-5CC66C66-F618-40D8-9264-D77EF1C85498Q51325304-3C71EBF3-2733-4EDF-B03C-0D62C0F387FDQ51433786-1B26CF7C-A2B0-4919-9CEB-8FFFC039FB92Q53162431-E49A77DE-8086-43E1-A75D-57AB9C453B11Q54619624-E04A0070-F0A1-40B4-8C3C-BCFAE0A5C6DEQ73263771-41E766B6-C277-4630-8C0E-AF21CF01E548Q79185397-9F3F737E-438C-49BF-84FE-A4CD7C27D669Q83181392-BFFFDBB1-6765-4BE8-8867-A59600AB25AAQ85186127-0C5170F8-0D87-4E18-8F7C-2B4BFE81E46BQ85186135-369CB08E-161E-49A0-9254-41B68A5D0960
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Burçak Karaca
@ast
Burçak Karaca
@en
Burçak Karaca
@es
Burçak Karaca
@nl
Burçak Karaca
@sl
type
label
Burçak Karaca
@ast
Burçak Karaca
@en
Burçak Karaca
@es
Burçak Karaca
@nl
Burçak Karaca
@sl
altLabel
Şaziye Burçak Karaca
@en
prefLabel
Burçak Karaca
@ast
Burçak Karaca
@en
Burçak Karaca
@es
Burçak Karaca
@nl
Burçak Karaca
@sl
P106
P31
P496
0000-0003-2638-1625